Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb & Co (NYSE:BMY) released data from the KRYSTAL-1 study on Krazati (adagrasib) combined with cetuximab for KRASG12C-mutated colorectal cancer, showing promising results. The FDA accepted a supplemental new drug application for this combination, with a review goal date set for June 21, 2024. Additionally, BMY announced positive results from the KRYSTAL-12 study on Krazati as a monotherapy for non-small cell lung cancer. BMY shares slightly declined by 0.27% to $51.18.
April 08, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb & Co released promising data on Krazati for colorectal cancer and announced FDA's priority review for a new drug application. Positive results were also shared from another study on Krazati for lung cancer. However, BMY shares dropped slightly.
The positive results from the KRYSTAL-1 and KRYSTAL-12 studies on Krazati for treating colorectal and lung cancer, respectively, along with the FDA's acceptance of a supplemental new drug application for priority review, are significant developments for Bristol Myers Squibb. These developments are likely to have a positive impact on the company's stock in the short term, despite the slight decline in share price following the announcement. The decline could be attributed to market volatility or other external factors not directly related to the company's operational performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100